| 摘要 |
The pharmaceutical composition contains a) prostacyclin, dihydroprostacyclin or a pharmaceutically acceptable salt of these compounds and b) a phosphodiesterase inhibitor. The pharmaceutical composition can also contain pharmaceutically acceptable vehicles or ancillary substances. It is produced in each case by mixing the components. The pharmaceutical composition can be used to prevent or reduce to a minimum the aggregation of platelets in blood, in blood products or in blood substitutes. It can be used for the treatment of thrombosis, gastric lesions and wounds. In addition, it can be employed in an extracorporeal circulation and in blood-separation methods.
|
